Genetic variation in antipsychotic drug targets could underlie variability among patients in the time required for antipsychotic effects to be elicited. In a clinical, pharmacogenetic study we focused on the dopamine receptor interacting protein (DRIP) gene family. DRIPs are pivotally involved in regulating dopamine receptor signal transduction. Consecutively hospitalized, acutely psychotic patients with DSM-IV schizophrenia (n=121) were included in the study if they received treatment with typical antipsychotic medication (TYP, n=72) or TYP plus risperidone (TYP-R, n=49) for at least 2 wk. Clinical state and adverse effects were rated at baseline and after 2 wk. Patients improved significantly on both TYP and TYP-R with no significant difference between them. Early responders were defined as patients whose PANSS change scores were greater than the median. Twenty-two single nucleotide polymorphisms (SNPs) were analysed in five DRIP-encoding genes. Two SNPs in NEF3, which encodes the DRIP, neurofilament-medium (NF-M), were associated with early response (rs1457266, p=0.01 ; rs1379357, p=0.006). A 5 SNP haplotype spanning NEF3 was over-represented in early responders (p=0.015), in the combined patient group and in the TYP group alone. These findings suggest that variation in NEF3, most likely functional variants that are in linkage disequilibrium with the SNPs that we studied, influences rate of response to TYP. Since NEF3 is primarily associated with dopamine D 1 receptor function, the evidence for a complementary role of dopamine D 1 receptors in antipsychotic effects is considered. The findings reported here open an interesting research avenue in the pharmacogenetics of antipsychotic effects but require replication in larger samples treated in a controlled context.
Introduction
Although antipsychotic medications have been in use for more than 50 yr, the time of onset of their clinical action remains a fundamental question. It was initially believed that early therapeutic effects were a reflection of non-specific reduction in agitation, excitement, and uncooperativeness. A recent meta-analysis encompassed data from 7450 patients in 42 double-blind, active-drug or placebo-controlled trials and found that significant improvement in psychosis was present by the end of the first week and exceeded that observed in each subsequent week (Agid et al., 2003) . Mean reductions in total scores on the Brief Psychiatric Rating Scale and the Positive and Negative Symptoms Scale (PANSS ; Kay et al., 1987) were 13.8 % during week 1, 8.1 % during week 2, 4.2 % during week 3, and 4.7 % during week 4. Considerable variance was evident suggesting that there may be a subgroup of patients who demonstrate earlier response.
Recent studies suggest that genetic variation in several receptors may contribute to inter-individual variability in therapeutic response to antipsychotic medication. The dopaminergic system is a primary target for analysis in this regard. Significant association with favourable treatment response to chlorpromazine was noted for the x141CIns allele of the dopamine D 2 receptor (DRD2) x141C Ins/Del polymorphism (Wu et al., 2005) and favourable response to haloperidol was associated with heterogyozity of the DRD2 TaqIA polymorphism (Schäfer et al., 2001) . Suzuki et al. (2000) found that response to 3-wk treatment with the substituted benzamide, nemonapride, was associated with the A1 allele of TaqIA polymorphism of DRD2.
The dopamine D 3 receptor gene (DRD3) has been fairly extensively studied in relation to response to antipsychotic treatment, in particular the Ser9Gly polymorphism. Association of the Ser9 allele with response to typical antipsychotics and of the Gly9 allele with response to atypical antipsychotics has been reported (Scharfetter et al., 1999) . DRD3 Ser9Gly polymorphism has also been associated with symptom severity in first-episode schizophrenic patients as well as with short-term outcome, carriers of the heterozygous genotype manifesting more severe psychotic symptoms on admission and greater improvement after antipsychotic treatment (Reynolds et al., 2005) . Compared to patients with the Gly9Gly genotype, those with either Ser9Ser or Ser9Gly had better response to risperidone on negative symptoms (Lane et al., 2002) . Complementing data from a previous study (Shaikh et al., 1996) , Scharfetter et al. (1999) analysed a group of patients with schizophrenia receiving clozapine and found Ser9Ser genotypes of DRD3 more prevalent in non-responders, Ser9Gly genotypes more prevalent in responders and Gly9Gly genotypes exclusively in responders to the medication. However, association of the DRD3 Gly allele with treatment response to clozapine was not observed in other studies (Dahmen et al., 2001 ; Malhotra et al., 1998) . Staddon et al. (2002) reported an association of DRD3 polymorphisms (Ser9Gly substitution and a novel polymorphism in the promoter region of DRD3, x205A/G) with improvement in positive, but not negative, symptoms following olanzapine treatment. Regarding the dopamine D 1 receptor, a combined genetic-imaging study has suggested that brain metabolic and clinical response to clozapine are related to D 1 receptor genotype (Potkin et al., 2003) . In a small sample of adolescent patients treated with risperidone, no significant association was found between DRD4 genotype and clinical response (Zalsman et al., 2003) .
Lack of association of DRD4 with clozapine response was also reported by Kohn et al. (1997) .
With respect to the serotonergic system, Sodhi et al. (1995) found a polymorphism (68G/C) of the 5-HT 2C receptor gene to be associated with response to clozapine in schizophrenic patients resistant to classical antipsychotic medication. This polymorphism was one of a combination of six that appeared to provide strong predictive value for response to clozapine (Arranz et al., 2000) . The His452Tyr HTR2A polymorphism may also be involved in clozapine response (Masellis et al., 1998) . It has also been reported that the T102C polymorphism of HTR2A may influence individual responses to risperidone (Lane et al., 2002) .
Given the prominent and well-documented role of dopamine in schizophrenia and psychosis (Carlsson et al., 2001) , it is appropriate to investigate additional candidate genes associated with its function. This is especially important with regard to early onset of antipsychotic medication response considering findings from a study by Abi-Dargham et al. (2000) indicating levels of synaptic dopamine to be predictive of good treatment response of 'positive symptoms ' to antipsychotic medication. In the current study we focus on genes coding for proteins that play a role in the neuronal response to dopamine through regulation of dopamine receptor activity. The candidate genes selected belong to the recently characterized dopamine receptor interacting protein (DRIP) gene family. The diverse DRIP family affects many aspects of dopamine receptor activity (Bergson et al., 2003) . DRIPs are involved in regulating the dopamine receptor signal transduction pathway and serve as scaffold proteins and adaptors. Through protein-protein interaction, they regulate manifold aspects of dopamine receptor biology, from biosynthesis and trafficking to desensitization (Bergson et al., 2003) . Factors that influence dopamine-mediated signalling could influence response to antipsychotic medication ; genes encoding DRIPs are thus potentially important candidate genes for the pharmacogenetics of antipsychotic response.
Abnormal levels of DRIPs have been reported in post-mortem studies of brain tissue from schizophrenia patients. The DRIPs, calcyon and neuronal Ca 2+ sensor 1 (NCS-1), were found to be up-regulated in the dorsolateral prefrontal cortex of patients with schizophrenia (Bai et al., 2004 ; Koh et al., 2003a,b) . These findings did not appear to be related to dose of antipsychotic treatment during the lifetime of the patients nor to factors such as age, gender and postmortem effects. Increased NCS-1 expression may result in overactive D 2 receptor signalling. This in turn may help explain the efficacy of D 2 receptor antagonists in treating the positive symptoms of schizophrenia (Bergson et al., 2003) . Recently, decreased levels of the DRIP, spinophilin, were observed postmortem in the hippocampal formation of schizophrenia patients (Law et al., 2004) . The effect of calcyon to potentiate calcium-dependent signalling has been proposed as potentially contributing to D 1 receptor-modulated cognitive functions of prefrontal cortex (Lezcano et al., 2000) . There have been few studies on genetic variations in DRIPs in schizophrenia patients. One study failed to show association of the illness with two polymorphisms in the calcyon gene (Luo et al., 2004) . Point mutations in the NEF3 gene have been identified in patients with Parkinson's disease, but no association of these and other variants within NEF3 with Parkinson's disease have been shown as yet (Han et al., 2005 ; Kruger et al., 2003 ; Lavedan et al., 2002) .
In this study we investigated a consecutively recruited sample of schizophrenia patients admitted to hospital with acute psychosis and treated with typical antipsychotic medication, alone (TYP) or in combination with risperidone (TYP-R), in the context of a naturalistic protocol. These two medication regimens were selected because they are the most commonly used in Israel. Health policy guidelines still encourage the use of typical antipsychotic medication and use of risperidone only once this regimen has failed. Thus, patients who have developed an acute psychosis while on typical antipsychotic medication are likely to have risperidone added after admission to hospital. We genotyped a panel of SNPs in five candidate genes from the DRIP family in order to determine their relationship to early therapeutic response and adverse effects.
Patients and methods

Clinical methods
The study sample consisted of in-patients with schizophrenia (as defined by DSM-IV) admitted to the Beer Yaakov Mental Health Center (a large state referral facility) in an acute psychotic state. Subjects were between the ages of 18 and 65 yr, male or female, Jewish, with information regarding Ashkenazi or non-Ashkenazi origin recorded. Diagnoses were established by means of a structured interview according to the Structured Clinical Interview for DSM-IV Axis I, Patient Edition (First et al., 1994) by two board-certified psychiatrists. Patients with evidence of neurological or medical conditions that could impact upon the outcome of antipsychotic treatment or be associated with a propensity to develop adverse effects were excluded from study participation. Patients with a history of substance or alcohol dependence or abuse were excluded. All subjects provided written informed consent after receiving a full explanation regarding the nature of the study and potential risks and benefits of participation. A psychiatrist independent of the study documented decisional capacity. The Beer Yaakov Mental Health Center Institutional Review Board and the Ministry of Health Ethical Review Board approved the study.
The design of the study was naturalistic. Only patients whose treating physicians prescribed TYP or TYP-R were included. A blood sample (30 ml) was obtained and transferred to the laboratory for DNA extraction. Clinical ratings were performed at baseline and again after 2 wk, provided that the patient continued to receive the same antipsychotic drugs during this period, although not necessarily at the same dose. All the patients were rated by the same clinician. Clinical outcome was rated with the PANSS. Adverse effects were evaluated with the Simpson-Angus Scale (Simpson and Angus, 1970) , Abnormal Involuntary Movements Scale (AIMS ; Guy, 1976 ) and the Barnes Akathisia Scale (Barnes, 1989) .
Genotyping
The focus of this work was on five DRIP encoding genes :
The single nucleotide polymorphisms (SNPs) used in the study were selected from three different databases : dbSNP, Ensemble, Genome Browser and Sequenom RealSNP. We selected SNPs that fulfilled the following criteria : (1) located within the gene of interest or no more than 20 000 bases upstream or downstream ; (2) reported heterozygosity of >0.1. The heterozygosity of the selected SNPs was checked by genotyping 24 Jewish Israeli control subjects and was found appropriate. Altogether 29 SNPs fulfilled these conditions. SNPs that showed significant deviation from Hardy-Weinberg equilibrium (HWE) (n=3) or significant differences between Ashkenazi and nonAshkenazi subjects (n=4) were excluded from further analysis. A list of the 22 SNPs that were included in the analysis, with details of their location and minor allele frequency (MAF) in our sample, is provided in Table 3 . Location of the SNPs typed in the NEF3 gene relative to the gene is shown in Figure 1 .
SNP genotyping was performed with a highthroughput system of chip-based mass spectrometry (matrix-assisted laser desorption/ionization timeof-flight ; MALDI-TOF) (Sequenom, San Diego, CA, USA). The allele determination in the sampled DNA was based on MALDI-TOF mass spectrometry of allele-specific primer products (Little et al., 1997a,b) . Genotyping assays were designed as multiplex reactions using SpectroDESIGNER software version 2.0.7 (Sequenom). Primers were synthesized by Integrated DNA Technologies (Coralville, IA, USA). The detailed PCR and primer extension reactions were according to the protocol for high multiplex homogeneous MassEXTEND (hME) procedure (Sequenom application notes, and described in McCullough et al., 2005) . The high-throughput liquid handling was performed with the aid of a MULTIMEK 96 automated 96-channel robot (Beckman Coulter, Fullerton, CA, USA). Primer extension products were loaded onto a 384-element chip (SpectroCHIP ; Sequenom) by nanolitre pipetting robot (SpectroPOINT, Sequenom) and analysed with a MassARRAY mass spectrometer (Bruker Daltonik, Bremen, Germany). The resulting mass spectra were processed and analysed for peak identification and allele determination with the MassARRAY TYPER version 3.1.4.0 software (Sequenom). About 10 % of the total calls were given a low score by the Sequenom caller software, and were inspected manually for the correct call.
Statistical analysis
Ratings of clinical state and adverse effects were analysed at baseline and after 2 wk for patients whose treatment regimen was constant during this time and consisted of TYP or TYP-R. SPSS version 12.01 (SPSS Inc., Chicago, IL, USA) was used to perform Student's t tests, x 2 tests or analysis of variance (ANOVA). The primary outcome variable was the PANSS change score calculated by subtracting the score at 2 wk from the score at baseline. For categorical analyses patients with change scores above the median were grouped as early responders (ERs) and patients with scores at or below the median as non-early responders (N-ERs).
Haploview (version 3.12) was used to detect significant departure from HWE and determine allele frequency differences between Ashkenazi and nonAshkenazi subjects. Haploview was also used to perform single SNP association tests, haplotype block analysis, haplotype population frequency estimation and haplotype association tests. p values <0.05 (two tailed) were regarded as nominally significant. Bonferroni correction was applied for the number of tests performed.
Analysis of the power of our sample (Power and Precision V2.0, 2000 ; http://www.powerandprecision. com) revealed that with 240 chromosomes divided approximately equally between the ER and N-ER groups, the smallest allele frequency difference that could be detected with 80 % power (a=0.05, two tailed) ranged from 0.11 [95 % confidence interval (CI) 0.03-0.19] to 0.17 (95 % CI 0.05-0.29).
Results
Demographic features, clinical history at baseline and drug treatment regimens during the study were compared between the ER (n=61) and N-ER (n=60) groups (Table 1) . There was no significant difference in age, gender, education, age at onset and at first hospitalization and cumulative psychiatric hospitalization (corrected for years of illness) between the groups. In terms of antipsychotic treatment, there was no significant difference between ERs and N-ERs in treatment with TYP or TYP-R, typical antipsychotic dose in chlorpromazine units, risperidone dose in the TYP-Rtreated patients and in the proportion of patients treated with two typical antipsychotics or receiving concomitant benzodiazepines or anticholinergics. The typical antipsychotics administered were : zuclopenthixol (52.4 %), haloperidol (20.2 %), perphenazine (11.5 %), clotiapine (10.6 %), fluphenazine (8.7 %), flupenthixol (2.9 %), levomepromazine (2.4 %), chlorpromazine (1.0 %), sulpiride (1.0 %), and penfluridol (1.0 %). There was no significant difference between the groups on the PANSS total score or on the PANSS positive, negative and general subscales at baseline (Table 2 ). There was also no significant difference between the groups in their scores on the SimpsonAngus, AIMS and the Barnes Akathisia scales at baseline (Table 2 ). Table 2 also shows the change scores (baseline score minus scores at 2 wk) for the PANSS total and subscales and for the SimpsonAngus, AIMS and Barnes Akathisia scales. Early response was not differentially related to treatment with TYP or TYP-R. Percent change in PANSS total score from baseline to 2 wk was 12.1¡15.4 % for all the patients, 12.0¡11.6 % for the TYP patients and 12.3¡19.7 % for the TYP-R patients. Analyses of allele and genotype frequencies for the individual SNPs in the five DRIP genes are shown in Table 3 , comparing ERs and N-ERs according to the total PANSS score at 2 wk. (Detailed genotype numbers are available from the authors on request.) Nominally significant differences in allele and genotype frequency were observed for two SNPs in the NEF3 gene (rs1457266, p=0.01 and p=0.02 respectively ; and rs1379357, p=0.006 and p=0.02 respectively). There were no significant findings in the other DRIP genes.
Details of linkage disequilibrium between the SNPs are given in Table 4 . No haplotype blocks were defined by the confidence interval algorithm of Gabriel et al. (2002) . We performed haplotype analysis of all five SNPs tested in the NEF3 gene (Table 5) . A CCCGC haplotype made up of rs196875-C, rs1457266-C, rs12515-C, rs1379357-G and rs196843-C (frequency in Table 6b . These included two or more of the rs196875-C, rs1457266-T, rs12515-T, rs1379357-C and rs196843-C alleles. As shown in Table 5 , there was a trend for the full 5 SNP CTTCC haplotype to be overrepresented in N-ERs (ER : N-ER ratio 0.14 : 0.26, p=0.057).
Separate analysis was performed of the patients treated with TYP or TYP-R. The same two SNPs in NEF3 that were associated with early response in the TYP and TYP-R groups combined were associated with early response in the TYP group alone (alleles, rs1457266 : x 2 =5.27, p=0.02 ; rs1379357 : x 2 =8.33, p= 0.004 ; genotypes, rs1457255 : x 2 =8.705, p=0.013 ; rs1379357 : x 2 =10.887, p=0.004). The 5 SNP haplotype (CCGCC) that was overrepresented in ERs in the combined group was overrepresented in ERs in the TYP group (ER : N-ER ratio 0.56 : 0.32, x 2 =6.52, p= 0.010). There were no significant associations of single SNPs or haplotypes with early response in the TYP-R group.
Analysis of the PANSS subscales revealed association of three SNPs in NEF3 with response to treatment at 2 wk as reflected in the PANSS positive subscale (alleles, rs196875 : x 2 =5.47, p=0.02 ; rs1457266 : x 2 =4.73, p=0.03 ; rs1379357 : x 2 =7.37, p= 0.007 ; genotypes, rs196875 : x 2 =6.455, p=0.04 ; rs1457266 : x 2 =5.293, p=0.071 ; rs1379357 : x 2 =9.285, p=0.01). Three SNPs were associated with negative symptom response (alleles, rs12515 : x 2 =5.06, p=0.03 ; rs1379357 : x 2 =4.32, p=0.04 ; rs196843 : x 2 =4.84, p= 0.03 ; genotypes, rs12515 : x 2 =5.056, p=0.08 ; rs1379357 : x 2 =3.935, p=0.14 ; rs196843 : p=0.02, Fisher's exact test). Haplotype analysis did not show significant association with early positive symptom response of the 5 SNP haplotype (CCGCC) that was associated with early response on the PANSS total scale. However, non-early response at 2 wk on the PANSS negative symptom subscale was associated with overrepresentation of the CTTCC haplotype (ER : N-ER ratio 0.13 : 0.28, x 2 =7.30, p=0.007). We also performed parametric analyses in which the PANSS subscale and total change scores at 2 wk were compared by genotype for each of the five SNPs in the NEF3 gene (Table 7) . The results showed a No significant associations of DRIP genes with treatment-emergent extra-pyramidal symptoms (EPS) were observed (data not shown). As noted, there was no significant change in scores on the Simpson-Angus, AIMS and the Barnes Akathisia scales over the course of 2 wk treatment with TYP or TYP-R.
Discussion
In the context of a prospective, pharmacogenetic study, we examined the association of early clinical response and treatment-emergent adverse effects with common genetic variants in five genes encoding DRIPs. The study sample consisted of acutely psychotic, in-patients with schizophrenia treated according to clinical considerations with TYP or TYP-R. We found nominally significant association of two SNPs in the NEF3 gene with early response and identified a 5 SNP haplotype in this gene that was significantly overrepresented in ERs after correction for multiple testing. The haplotype encompassed both nominally significant single SNPs. Further testing revealed that almost all consecutive combinations of the 5 SNPs encompassed in the larger haplotype were associated with early response. A second haplotype anchored in these five SNPs showed a trend towards overrepresentation in N-ERs. Several consecutive sub-elements of this haplotype were overrepresented in N-ERs at a nominally significant level. These findings support the hypothesis that genetically based variation in the DRIP, NEF3, influences the rate of clinical antipsychotic response to typical antipsychotic medication and suggests that those patients who carry specific genetic variants may be more likely to respond early than those who do not.
The potentially important clinical implication of these findings is that genotype analysis could provide the opportunity to identify a priori those patients who are more likely to respond earlier and to design treatment accordingly. Individualization of therapy based on the genetic profile of the patient is the overall aim of psychiatric pharmacogenetics and pharmacogenomics Lerer and Macciardi, 2002 ; Malhotra et al., 2004) . Typical antipsychotics are still widely used worldwide (Emsley et al., 1999) although the trend has moved strongly towards the use of atypical agents for the first-line treatment of acute schizophrenic psychosis (Miyamoto et al., 2005) . Adverse effects of typical antipsychotics, EPS in particular, are one of the major factors that have motivated this trend. There is an accumulating body of data supported by metaanalyses which suggests that susceptibility to the most severe extrapyramidal effect of typical antipsychotics, tardive dyskinesia, may be amenable to pharmacogenetic prediction (Lerer et al., , 2005 Muller et al., 2004) . Thus, it may ultimately be possible to prospectively identify a subgroup of patients who could be candidates for treatment with typical antipsychotic medication on the basis of their anticipated clinical response and adverse effect profile as predicted by their genotypes. In view of the fact that atypical antipsychotics also have significant adverse effects, the option of prescribing typical antipsychotic medication would be an important clinical advantage.
These conclusions should be tempered with reservations regarding the limitations of the current study, which was open in design. In the absence of a placebo group it cannot be concluded definitively that the association of early response with the NEF3 gene that we observed was specific to the treatment administered. An illustrative example in this regard concerns the widely reported association of response to specific serotonin reuptake inhibitors (SSRIs) with an insertion deletion polymorphism in the promoter of the serotonin transporter gene (see Smits et al., 2004 ; Serretti and Artioli, 2004, for review) . In the only study to address the issue of placebo response, Rausch et al. (2002) showed that response to placebo was associated with the promoter variant as was response to SSRIs. A further limitation of the current study is that prescription of antipsychotic medication was not according to a pre-defined protocol. Several different typical antipsychotics were used at varying doses. About a third of the patients were administered risperidone concurrently with typical antipsychotics. Our clinical analyses did not indicate a difference between patients administered typical antipsychotic medication alone and those administered risperidone as well in terms of early response. Association of early response with the NEF3 gene was significant in the overall group and in the patients administered typical antipsychotics only. The sample size of the group receiving typical antipsychotics plus risperidone may not have been large enough to demonstrate an effect in this group separately. Further pharmacogenetic studies are needed in order to tease apart these issues, particularly studies in which specific antipsychotic agents and risperidone are administered as monotherapy. It should also be emphasized that the results of the current study relate to early response only. DRIP genes not associated with early response in our study could influence longerterm outcome. Our study is ongoing and when sufficient patients complete the full study period of 6-8 wk (subject to the constraints of a naturalistic design), it will be possible to address these issues. The power of our sample is an important consideration in regard to those genes for which we did not find any association of SNPs with the clinical variables examined. The minimum allele frequency difference between ERs and N-ERs that we could exclude with 80 % power was 11-17 %. Thus, the potential for type II error must be borne in mind and our failure to demonstrate association of DRIPs other than NEF3 with response to antipsychotic treatment at 2 wk, cannot be regarded as definitive. In terms of type I error, two considerations should be considered. The first is that spurious factors could be responsible for the association of NEF3 with treatment response that we observed. We excluded from the analysis all SNPs that were not in HWE. We included only Jewish subjects both of whose parents were of Ashkenazi or nonAshkenazi origin and excluded from the analysis those SNPs that showed a significant difference in allele frequency between Ashkenazi and nonAshkenazi subjects. Nevertheless, replication of our finding by other groups will be a pivotal test of its validity. A further consideration in relation to the possibility of type I error is the possibility of spurious results due to multiple statistical comparisons. There is no clear consensus as to the appropriate approach to correct for multiple testing although it is widely agreed that correction is essential. We performed 22 statistical tests for the association of individual SNPs in the five DRIP genes that we studied with early response to antipsychotic treatment. Conservative Bonferroni correction would require an a of <0.0023 in order to consider the results significant. While we did observe nominally significant association (p<0.05) of alleles and genotypes of two SNPs in NEF3 with response to antipsychotic treatment, the p values obtained would not survive correction. For testing of haplotypes we limited our analysis a priori to SNPs in the NEF3 gene in which two individual SNPs were nominally significant. We tested the association of a haplotype derived from the combination of all five SNPs in this gene with early response to antipsychotic treatment. One 5 SNP haplotype combination out of three tested was significant after correction, supporting an association of the NEF3 gene with early response to antipsychotic treatment. If correction were made for all SNPs tested as well as all haplotypes, the finding would not remain significant.
The SNPs and haplotypes in NEF3 that were associated with early response to antipsychotics in our study do not alter the structure of the gene and are not known to influence its function. Because NEF3 has a relatively small size (5299 bp) (Figure 1 ), only one of the five SNPs is located within the gene itself (rs12515 in the 3k UTR). Two SNPs are located upstream of the NEF3 locus (rs196875, rs1457266) and two are located downstream (rs1379357, rs196843), all in the 20 000 bp flanking regions. The 5 SNP, CCCGC haplotype associated with early response thus spans the entire gene. The association is probably a consequence of linkage disequilibrium between the SNPs we studied and as yet unidentified variants that influence structure and/or function and are located in the coding or regulatory regions of the gene. Of note in this regard, a recent study indicated that haplotypes made up of non-coding SNPs in the dysbindin gene, which has been associated with susceptibility to schizophrenia in several studies, influence the expression the gene in human brain (Bray et al., 2005) . This effect is most likely a manifestation of linkage disequilibrium with causative variants but could also represent a direct effect on gene expression, the mechanism of which is still unknown.
The neurobiological role of the NEF3 gene renders it a potentially important functional candidate for a role in response to antipsychotic medication. It is located on chromosome 8p21.2, spans 5299 bp and contains three exons. NEF3 encodes NF-M (neurofilament medium, 90 kDa), one of five major intermediate filament (IF) proteins that are expressed in mature neurons -the three neurofilament proteins (NF-L, NF-M and NF-H), a-internexin and periphrein. Neurofilaments are obligate heteropolymers, requiring NF-L together with either NF-M or NF-H for proper polymer formation (Lariviere and Julien, 2004) . Structurally, NF-M has a central rod domain of y310 amino-acid residues that form a highly conserved a-helical region. The central rod domain is flanked by amino terminal (head), and C-terminal (tail) domains (Ludemann et al., 2005) . According to Kim et al. (2002) , NF-M interacts specifically with the third cytoplasmic loop of the dopamine D 1 receptor, via the C end of the tail domain. NF-M interacts weakly with D 5 receptors, but no interaction has been detected with any of the D 2 subfamily of receptors. Co-localization of NF-M and the D 1 receptor was shown in several rat brain regions. NF-M overexpression reduced D 1 receptor expression at the cell surface and promoted accumulation of the receptor in the cytosol. At the same time, D 1 receptors at the cell surface were resistant to agonist-induced desensitization (Kim et al., 2002) . Similar interaction patterns are presented by calcyon, which interacts with the D 1 receptor but not with the D 2 receptor subfamily. The other DRIPs checked in this study, interact with D 2 but not with D 1 (Bergson et al., 2003) . The five neurofilament genes have been proposed to play a role in human neuronal development and disease, including amyotrophic lateral sclerosis (ALS), Parkinson disease and neuropathies (Lariviere and Julien, 2004) . Differences in the phosphorylation levels of NF-M and NF-H were detected in the brains and CSF of Alzheimer patients (Hu et al., 2002 ; Wang et al., 2001) . In an animal model of ALS, O-glycosylation of NF-M was found to be decreased (Ludemann et al., 2005) .
The fact that NEF3 and its protein product, NF-M, are associated with dopamine D 1 receptors requires further consideration in the context of our finding that this gene is associated with response to typical antipsychotic medication. It is well established that the clinical potency of typical antipsychotics directly correlates with their affinity for dopamine D 2 receptors (Creese et al., 1976) . In vivo, D 2 receptor occupancy by typical antipsychotics is of the order of 70 % or more while D 1 receptor occupancy is considerably lower and varies among different drugs (Wiesel et al., 1990) . Moreover, the dopamine D 1 receptor antagonist, SCH 39166, was found to lack antipsychotic effects in clinical trials (Karlsson et al., 1995) . Nevertheless, a possibly important, more complex role of D 1 receptors is under increasing consideration. Clozapine, the prototypical atypical antipsychotic, is thought to be more effective clinically than typical antipsychotics and also the newer atypical agents. Clozapine occupies D 2 receptors in the striatum to a significantly lesser extent than typical and atypical agents and D 1 receptors to a significantly greater extent (Farde et al., 1992 ; Tauscher et al., 2004 ; Wiesel et al., 1990) . The ratio of striatal D 1 /D 2 occupancy for clozapine was 0.88, substantially higher than for olanzapine (0.54), quetiapine (0.41), or risperidone (0.31) (Tauscher et al., 2004) , suggesting an important role for both D 1 and D 2 receptors in the unique clinical profile of this drug (Tauscher et al., 2004 ; Wiesel et al., 1990) . These results are based on PET imaging studies of the corpus striatum. Findings regarding the effects of antipsychotic drugs in the cerebral cortex provide a further intriguing perspective (Lidow et al., 1998) . While D 2 receptors in the cortex are up-regulated by typical antipsychotics (in the case of clozapine to a significantly greater extent than in the striatum), D 1 receptors appear to be down-regulated after prolonged treatment. These observations are consistent with the view that schizophrenia may be associated with an imbalance of the dopaminergic system involving both D 1 and D 2 receptors (Abi- Dargham and Laruelle, 2005) . Thus, genetic variation in NEF3, which encodes a DRIP that affects D 1 receptor function, could conceivably influence the clinical effect of antipsychotic medication including an earlier onset of action, as observed in the present study. In this regard it is interesting to note that more than 70 % of the typical antipsychotics administered to patients in the study were agents with a relatively high affinity for D 1 receptors such as thioxanthenes or phenothiazines (Farde et al., 1992 ; Leysen et al., 1993) .
Although the findings reported in this paper are preliminary and require replication in larger samples of patients receiving uniform treatment with typical antipsychotic medication or risperidone, they point to a potentially important new research direction. Possible effects of NEF3 gene variation on the clinical action of clozapine would be a particularly intriguing question to address. Also, the role of NEF3 and other DRIP genes in the longer-term outcome of antipsychotic treatment remains to be studied. Tailoring of antipsychotic treatment to the pharmacogenetic profile of the individual patient is an objective that renders eminently worthwhile the considerable efforts that will need to be invested.
